cyclophosphamide

Type: Keyphrase
Name: cyclophosphamide
First reported 7 hours ago - Updated 7 hours ago - 1 reports

Method for the administration of anti-cancer drugs

An administration method comprising: determining a cancer type through (i) first data indicating that an Estrogen Receptor (ER) is negative and a Human Epidermal growth factor Receptor-2 (Her2) is negative, or (ii) second data indicating that at least ... [Published Free Patents Online - 7 hours ago]
First reported Oct 16 2014 - Updated Oct 17 2014 - 1 reports

Sangamo BioSciences ZFP Therapeutic Program In HIV/AIDS Featured At Three Major Scientific Conferences In October 2014

Sangamo BioSciences, Inc. (NASDAQ: SGMO) announced that Company scientists and clinicians, as well as academic collaborators, were invited speakers at three major scientific meetings in Europe and the United States. Their presentations covered a number ... [Published Benzinga.com - Oct 16 2014]
First reported Oct 14 2014 - Updated Oct 14 2014 - 1 reports

Trial results show high remission rate in leukemia following immune cell therapy

Children and young adults with chemotherapy-resistant B-cell acute lymphoblastic leukemia (ALL) experienced high remission rates following treatment with an experimental immunotherapy. This finding, from an early-phase clinical trial, is important because ... [Published FirstWord Pharma - Oct 14 2014]
First reported Oct 14 2014 - Updated Oct 14 2014 - 1 reports

FDA Grants Approval to Velcade (bortezomib)

Millennium: The Takeda Oncology Company with its parent company, Takeda Pharmaceutical Company Limited, reported that the U.S. Food and Drug Administration (FDA) has approved Velcade (bortezomib) for injection for use in previously untreated patients ... [Published Individual.com - Oct 14 2014]
First reported Oct 10 2014 - Updated Oct 11 2014 - 2 reports

US FDA approves Velcade injection for use in previously untreated patients with MC

Millennium: The Takeda Oncology Company with its parent company, Takeda Pharmaceutical Company, announced that the US Food and Drug Administration (US FDA) has approved Velcade (bortezomib) for injection for use in previously untreated patients with mantle ... [Published PharmaBiz - Oct 11 2014]
First reported Oct 10 2014 - Updated Oct 10 2014 - 1 reports

Study: Race determinant of treatment preferences for patients with systemic lupus erythematosus

After adjustment for income, medications, expectations for medication efficacy and patients’ perceptions of physicians, race is an independent determinant of treatment preferences for patients with systemic lupus erythematosus, according to recently published ... [Published Orthopedics Today - Oct 10 2014]
First reported Oct 09 2014 - Updated Oct 10 2014 - 2 reports

FDA Approves Bortezomib (Velcade) for Untreated MCL

The US Food and Drug Administration (FDA) today approved bortezomib ( Velcade ; Millennium) for previously untreated patients with mantle cell lymphoma (MCL).The indication is an extension of the injectable drug's labeling, as bortezomib is already approved ... [Published American Journal of Public Health - Oct 10 2014]
First reported Oct 09 2014 - Updated Oct 09 2014 - 1 reports

Single-agent Cyclophosphamide for GVHD Prophylaxis

Hematopoietic stem cell transplantation can cure hematologic malignancies. The most significant obstacle to its success is graft vs host disease (GVHD), in which immunocompetent cells from the graft mount an immune response against the host that can ... [Published American Journal of Public Health - Oct 09 2014]
First reported Oct 07 2014 - Updated Oct 08 2014 - 3 reports

Cyclophosphamide drug can eliminate lifethreatening immune response after bone marrow transplants

Johns Hopkins and other cancer researchers report that a very short course of a chemotherapy drug, called cyclophosphamide, not only can prevent a life-threatening immune response in some bone marrow transplant recipients, but also can eliminate such ... [Published BioPortfolio - Oct 08 2014]
First reported Oct 06 2014 - Updated Oct 06 2014 - 1 reports

Chemotherapy risky for medical staff

Tadao Kakizoe / Special to The Yomiuri Shimbun Chemotherapy is one of the most widely known forms of cancer treatment. However, it is little known that medical practitioners, including nurses, pharmacists and doctors who are involved in preparing and ... [Published The Japan News - Oct 06 2014]
First reported Oct 03 2014 - Updated Oct 03 2014 - 1 reports

Further Evidence on the Favorable Role of the Anomeric Effect on the Cleavage of HepDirect and Cyclophosphamide Prodrugs

On the basis of previous conformational and configurational studies of 4-aryl-substituted cyclophosph(on)ates derived from d ... [Published Journal of Organic Chemistry - Oct 03 2014]
First reported Sep 28 2014 - Updated Sep 29 2014 - 3 reports

Order Cyclophosphamide Online With Free Dr Consultation, Cash On Delivery Of Cyclop

order cyclophosphamide online with free dr consultation, cash on delivery of cyclophosphamide no prescriptionMed Portal has proved its reliability and safety, working at pharmaceutical market since 2003. One of the most urgent problems in online pharmacy ... [Published Student Village - Sep 29 2014]

Quotes

"This long follow-up of patients shows that we have really altered the natural history of this disease," says Dr. Perez. "Herceptin works — and it works for a long period of time. The drug has impacted the lives of many women in the U S and worldwide."
...non-operational headwinds push the near-term 2015 sales and EPS outlook significantly lower," analysts Danielle Antalffy and Puneet Souda wrote. "Operationally, the only major incremental headwinds are coming from increasing cyclophosphamide competition - now most likely a 2015 event vs. initial expectations that BAX would almost entirely absorb this impact in 2014."
"Like cyclosporine," they conclude, "current new treatments, such as rituximab, are not curative. The discovery of new treatments with a curative mechanism is eagerly anticipated."
...developing a ZFP Therapeutic that may replicate natural, durable resistance to HIV infection," said Edward Lanphier, Sangamo's president and CEO. "Sangamo's ongoing Phase 2 trial incorporates all that we have learned from previous trials about the potential mechanism of this novel therapeutic clinical approach, and we believe the data produced will provide a clear path to pivotal studies. We expect to accrue all subjects onto the clinical trial by the end of 2014 and to present data in 2015."

More Content

All (127) | News (114) | Reports (0) | Blogs (11) | Audio/Video (0) | Fact Sheets (1) | Press Releases (1)
sort by: Date | Relevance
Preliminary Results of a Phase II Trial of Prot... [Published Journal of Clinical Oncology - 7 hours ago]
Method for the administration of anti-cancer drugs [Published Free Patents Online - 7 hours ago]
Trastuzumab continues to show life for HER2-pos... [Published EurekAlert! - 17 hours ago]
Years After Treatment for HER2-Positve Early St... [Published Newswise - 18 hours ago]
New Strategies Emerge for Managing CLL Patients... [Published OncLive - Oct 20 2014]
Will This Price Target Cut Hurt Baxter (BAX) St... [Published The Street Latest - Oct 20 2014]
Millennium’s Cancer Drug Velcade Scores Another... [Published FDA News - Oct 18 2014]
Updates on the Management of Autoimmune Blister... [Published General Medicine eJournal - Oct 17 2014]
Outlook Favorable in Relapsing Nephrotic Syndrome [Published American Journal of Public Health - Oct 17 2014]
Sangamo BioSciences ZFP Therapeutic Program In ... [Published Benzinga.com - Oct 16 2014]
Sangamo BioSciences ZFP Therapeutic Program in ... [Published CBS Detroit - Oct 16 2014]
Neuroendocrine (Small-Cell) Carcinomas: Why The... [Published Cancernetwork.com - Oct 16 2014]
Cancer survivor sees life through new set of eyes [Published Journal Pilot - Oct 16 2014]
Management of Young Breast Cancer Patients With... [Published Cancernetwork.com - Oct 16 2014]
Clinical Trials Actively Recruiting Patients Wi... [Published The ASCO Post - Oct 15 2014]
Pathologic Complete Response: Understanding the... [Published The ASCO Post - Oct 15 2014]
Exciting Highlights in Several Types of Lymphom... [Published The ASCO Post - Oct 15 2014]
Trial results show high remission rate in leuke... [Published FirstWord Pharma - Oct 14 2014]
¡Manos limpias, chicos sanos! [Published Bio-Medicine - Oct 14 2014]
Angioimmunoblastic T-Cell Lymphoma (AILT)/ Immu... [Published MyNewsDesk - Oct 14 2014]
FDA Grants Approval to Velcade (bortezomib) [Published Individual.com - Oct 14 2014]
Lipocine Announces Positive Results In Phase 2a... [Published BioMedReports - Oct 14 2014]
Clinical trials offer cancer patients hope [Published Cumberland Times-News - Oct 13 2014]
US FDA approves Velcade injection for use in pr... [Published PharmaBiz - Oct 11 2014]
Study: Race determinant of treatment preference... [Published Orthopedics Today - Oct 10 2014]
FDA Expands Velcade (Bortezomib) Label to Inclu... [Published PT Community - Oct 10 2014]
A question of life [Published stuff.co.nz - Oct 10 2014]
Velcade Approved For Treatment-Naïve Mantle Cel... [Published American Journal of Managed Care - Oct 10 2014]
FDA Approves Bortezomib (Velcade) for Untreated... [Published American Journal of Public Health - Oct 10 2014]
Single-agent Cyclophosphamide for GVHD Prophylaxis [Published American Journal of Public Health - Oct 09 2014]
1 2 3 4 5
In Focus
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
Content Volume
Document Volume
Network
Network

Blogs

sort by: Date | Relevance
Two-Day Drug Regimen Enough to Control Severe I... [Published Johns Hopkins Medicine News - Oct 07 2014]
Johns Hopkins and other cancer researchers report that a very short course of a chemotherapy drug, called cyclophosphamide, not only can prevent a life-threatening immune response in some bone marrow transplant recipients, but also can eliminate such ...
Biotech Stock Kite Phama Explodes Higher After ... [Published Clusterstock - Aug 25 2014]
Shares of Kite Pharma are exploding higher in after-hours trading. The $827 million biotech firm just revealed positive outcomes from patients with aggressive non-Hodgkin's lymphoma after receiving its anti-CD19 treatment. KITE is up 35%. "The ...
Stem Cell Transplantation [Published Multiple Sclerosis Research - Aug 17 2014]
Greco R, Bondanza A, Oliveira MC, Badoglio M, Burman J, Piehl F, Hagglund H, Krasulova E, Simões BP, Carlson K, Pohlreich D, Labopin M, Saccardi R, Comi G, Mancardi GL, Bacigalupo A, Ciceri F, Farge D. Autologous hematopoietic stem cell transplantation ...
Research and Markets: Cyclophosphamide (CAS 605... [Published Business Wire Manufacturing News - Aug 07 2014]
DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/63jzc7/cyclophosphamide) has announced the addition of the "Cyclophosphamide (CAS 6055-19-2, 50-18-0) Market Research Report 2014" report to their offering. Cyclophosphamide ...
Autologous hematopoietic stem cell transplantat... [Published Multiple Sclerosis Journal RSS feed -- OnlineFi ... - Jul 30 2014]
Background: Neuromyelitis optica (NMO) is an inflammatory autoimmune disorder of the central nervous system, hallmarked by pathogenic anti-aquaporin 4 antibodies. NMO prognosis is worse compared with multiple sclerosis. Objective: The European Group for ...
1 2 3

Press Releases

sort by: Date | Relevance
Nuvilex and Austrianova Announce Results of Cli... [Published GlobeNewswire: Acquisitions News - Jul 17 2014]
1
Contact Us
Sales
Support


Freebase CC-BY Some image thumbnails are sourced from Freebase, licensed under CC-BY

Copyright (C) 2014 Silobreaker Ltd. All rights reserved.
The selection and placement of stories and images on any Silobreaker page are determined automatically by a computer program.
The time or date displayed reflects when an article was added to or updated in Silobreaker.